Tablets 88micrograms, 180micrograms, 350 micrograms, 700micrograms pramipexole base (equivalent to 125micrograms, 250micrograms, 500micrograms and 1mg pramipexole salt)
Modified-release tablets 260 micrograms, 520 micrograms 1.05mg, 1.57mg, 2.1mg, 2.62mg, 3.15mg base (equivalent to 375micrograms, 750micrograms, 1.5mg, 2.25mg, 3mg, 3.75mg, 4.5mg salt)

Parkinson's disease.

Tablets 88micrograms, 180micrograms, 350 micrograms, 700micrograms pramipexole base (equivalent to 125micrograms, 250micrograms, 500micrograms and 1mg pramipexole salt)

Restless leg syndrome.

Recommended as the first line pharmacological treatment for restless leg syndrome, in line with the LSCMMG Restless Legs Syndrome Guidance.

Tablets 250micrograms, 500micrograms, 1mg, 2mg
Modified-release tablets 2mg, 3mg, 4mg, 6mg, 8mg

Parkinson's disease.

Tablets 250micrograms, 500micrograms, 1mg, 2mg

Restless leg syndrome.

Recommended as the second line pharmacological treatment for restless leg syndrome, in line with the LSCMMG Restless Legs Syndrome Guidance.

Patches 2mg/24 hours, 4mg/24 hours, 6mg/24 hours, 8mg/24 hours

Parkinson's Disease.

Rotigotine has shown inferiority to ropinirole and should not be used in preference to other dopamine agonists unless such alternative are not suitable (e.g. compliance issues, need for social care to administer other oral therapies, dysphagia), not tolerated (GI disturbance), or ineffective.

Patches 1mg/24 hours, 2mg/24 hours, 3mg/24 hours

Restless Legs Syndrome.

Recommended for restricted use in line with the LSCMMG Restless Legs Syndrome Guidance.

Dacepton 30mg/3mL Cartridges

Dacepton 100mg/20mL solution for infusion vials

APO-go POD 100mg/20mL solution for infusion cartridges

APO-go pre-filled syringes (PFS) will no longer be available from April 2025.

Capsules 100mg
Liquid 50mg/5mL

Parkinson's disease (but not drug-induced extrapyramidal symptoms).